« Return to News | Awards & Advancement

Lynn Kramer appointed chief clinical officer of Eisai Product Creation Systems

Friday, April 12, 2013 02:13 PM

Eisai has appointed Lynn Kramer, MD, to the newly created position of chief clinical officer of Eisai Product Creation Systems.

In this role, Kramer will be responsible for the approval of protocol designs of pivotal studies to achieve timely regulatory approval of competitive labels for new products, indications and life-cycle extensions. This includes the selection of study regions and clinical sites. He also will provide oversight of the design of Proof of Concept (POC) Studies for each of Eisai's Product Creation Units.

In addition to these new responsibilities, Kramer will continue to serve as president of the neuroscience and general medicine product creation unit, a position he has held since July 2009. In this capacity, Kramer is responsible for overseeing the full product creation cycle from discovery through regulatory approval of innovative projects in the neuroscience and general medicine areas.

Kramer joined Eisai in 2007 as executive vice president of global clinical research and was soon promoted to the additional role of COO of Eisai Medical Research. Upon the establishment of Eisai Product Creation Systems in 2009, he accepted a dual appointment as president of the neuroscience and general medicine product creation unit and also the scientific and operational clinical support (SOCS) core functional unit. He held the SOCS position until mid-2010.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.